BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS) https://t.co/dmTInGAzH2
Clinical Trial Update --Over 23 sites in 7 countries are live. First patients have been enrolled in both Europe and US. 600-person global phase 2 #clinicaltrial of recombinant human plasma #gelsolin (rhu-pGSN) for moderate to severe Acute Respiratory Distress Syndrome (#ARDS)
https://t.co/hCvSs9j6PI
Two independent studies explored #gelsolin's role in type 2 #diabietes. #Bioaegis' human recombinant plasma gelsolin is a host-directed approach to treating #inflammatorydiseases.
There are NO current therapies other than supportive care for #ARDS. We just received #FDA clearance to proceed with our #IND for #gelsolin 'inflammation regulatory protein' treatment. #lunginjury#inflammation#savinglives
https://t.co/3l2KXR0H96
We received #FDA clearance to proceed with our Investigational New Drug (#IND) for #gelsolin, for the treatment of acute respiratory distress syndrome (#ARDS).https://t.co/3l2KXR0H96
Received #FDA approval for our Investigational New Drug (#IND) application for our human protein, #gelsolin, for the treatment of acute respiratory distress syndrome. (#ARDS).https://t.co/3l2KXR0H96